Peter Davies

Peter Davies

Auto-generated profile, based on publicly available information

Peter Davies

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2003 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
CACathy Andorfer
Cathy Andorfer
YKYvonne Kress
Yvonne Kress
MEMarisol Espinoza
Marisol Espinoza
RSRohan De Silva
Rohan De Silva
KTKerry Lee Tucker
Kerry Lee Tucker
PDPeter Davies
Peter Davies

1 September 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
XCXiyun Chai
Xiyun Chai
SWSu Wu
Su Wu
TMTracey K. Murray
Tracey K. Murray
RKRobert Kinley
Robert Kinley
CCClaire V. Cella
Claire V. Cella
MCMartin Citron
Martin Citron
The microtubule-associated protein Tau plays a critical role in the pathogenesis of Alzheimer disease and several related disorders (tauopathies). In the disease Tau aggregates and becomes hyperphosphorylated forming paired helical and straight filaments, which can further condense into higher order neurofibrillary tangles in neurons. The development of this pathology is consistently associated with progressive neuronal loss and cognitive decline. The identification of tractable therapeutic targets in this pathway has been challenging, and consequently very few clinical studies addressing Tau pathology are underway. Recent active immunization studies have raised the possibility of modulating Tau pathology by activating the immune system. Here we report for the first time on passive immunotherapy for Tau in two well established transgenic models of Tau pathogenesis. We show that peripheral administration of two antibodies against pathological Tau forms significantly reduces biochemical Tau pathology in the JNPL3 mouse model. We further demonstrate that peripheral administration of the same antibodies in the more rapidly progressive P301S tauopathy model not only reduces Tau pathology quantitated by biochemical assays and immunohistochemistry, but also significantly delays the onset of motor function decline and weight loss. This is accompanied by a reduction in neurospheroids, providing direct evidence of reduced neurodegeneration. Thus, passive immunotherapy is effective at preventing the buildup of intracellular Tau pathology, neurospheroids, and associated symptoms, although the exact mechanism remains uncertain. Tau immunotherapy should therefore be considered as a therapeutic approach for the treatment of Alzheimer disease and other tauopathies.

26 August 2009 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MPManuela Polydoro
Manuela Polydoro
CAChristopher M. Acker
Christopher M. Acker
KDKaren Duff
Karen Duff
PCPablo E. Castillo
Pablo E. Castillo
PDPeter Davies
Peter Davies
A hallmark feature of Alzheimer's disease pathology is the presence of neurofibrillary tangles (NFTs), which are intracellular aggregates of conformationally abnormal and hyperphosphorylated tau. The presence of NFTs in the forebrain is associated with impairments of cognitive function, supporting a central role for tau in dementia. The significance of the accumulation of NFTs for neuronal and cognitive function is still obscure. It is possible that NFTs disrupt synaptic transmission and plasticity, leading to memory deficits and cognitive malfunction. To elucidate the relationship between the development of tau pathology and synaptic and cognitive functions, we performed behavioral tests and electrophysiological experiments in the htau mouse. Here we report age-dependent cognitive and physiological impairments in htau mice that preceded neurodegeneration. Twelve-month-old htau mice with moderate tau pathology, but not 4-month-old mice with early-stage tau pathology, presented cognitive deficits in an object recognition memory task in which the visual recognition memory of a novel object was disrupted. Moreover, only 12-month-old htau mice exhibit spatial memory deficits, as indicated by the impaired performance in the Morris water maze. In addition, we report that basal synaptic transmission and induction of long-term potentiation with high-frequency stimulation, but not theta burst stimulation, is perturbed in hippocampal CA1 region of old but not young htau mice. Our results suggest that tau pathology may underlie an age-dependent learning impairment through disruption of synaptic function.

1 September 2011 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
JGJesus J. Gomar
Jesus J. Gomar
Teresa Bobes-BascaránTeresa Bobes-Bascarán
Teresa Bobes-Bascarán
CCConcepcion Conejero-Goldberg
Concepcion Conejero-Goldberg
PDPeter Davies
Peter Davies
TGTerry E. Goldberg
Terry E. Goldberg
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
Research from JAMA Psychiatry — Utility of Combinations of Biomarkers, Cognitive Markers, and Risk Factors to Predict Conversion From Mild Cognitive Impairment to Alzheimer Disease in Patients in the Alzheimer's Disease Neuroimaging Initiative

3 June 2011 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
ABAllal Boutajangout
Allal Boutajangout
JIJohanna Ingadottir
Johanna Ingadottir
PDPeter Davies
Peter Davies
ESEinar M. Sigurdsson
Einar M. Sigurdsson
J. Neurochem. (2011) 118, 658–667. Targeting hyperphosphorylated tau by immunotherapy is emerging as a promising approach to treat tauopathies such as Alzheimer’s disease and frontotemporal dementia. We have previously reported that active tau immunization clears tau aggregates from the brain and attenuates or prevents functional impairments in two different tangle mouse models. Here, we assessed the efficacy of passive immunization with the PHF1 antibody, which targets a phospho‐epitope within one of our active immunogens. Homozygous female tangle mice (JNPL3, 2–3 months) were injected intraperitoneally once per week with PHF1 or pooled mouse IgG (250 μg/125 μL; n = 10 per group) for a total of 13 injections. Their behavior was assessed at 5–6 months of age and brain tissue was subsequently harvested for analyses of treatment efficacy. The treated mice performed better than controls on the traverse beam task (p < 0.03), and had 58% less tau pathology in the dentate gyrus of the hippocampus (p = 0.02). As assessed by western blots, the antibody therapy reduced the levels of insoluble pathological tau by 14–27% (PHF1, p < 0.05; PHF1/total tau, p < 0.0001) and 34–45% (CP13 or CP13/total tau, p < 0.05). Levels of soluble tau and sarkosyl soluble tau were unchanged, compared with controls, as well as total tau levels in all the fractions. Plasma levels of PHF1 correlated inversely with tau pathology in the brainstem (p < 0.01), with a strong trend in the motor cortex (p < 0.06) as well as with insoluble total tau levels (p < 0.02), indicating that higher dose of antibodies may have a greater therapeutic effect. Significant correlation was also observed between performance on the traverse beam task and PHF1 immunoreactivity in the dentate gyrus (p < 0.05) as well as with insoluble PHF1/total tau ratio on western blots (p < 0.04). These results show that passive immunization with tau antibodies can decrease tau pathology and functional impairments in the JNPL3 model. Future studies will determine the feasibility of this approach with other monoclonals and in different tangle models in which thorough cognitive assessment can be performed.

19 October 2010 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
VVValerie Vingtdeux
Valerie Vingtdeux
PDPeter Davies
Peter Davies
DDDennis W. Dickson
Dennis W. Dickson
Philippe MarambaudPhilippe Marambaud
Philippe Marambaud